Table 1 Characteristics of the PD and HD studies
Parameter | CIS-PD study | Open PRIDE-HD sub-study |
|---|---|---|
Patient sample size | 51 | 17 |
Study duration | 6 months | 6 months |
Remote compliance metrics | (1) Medication reporting (2) Symptoms reporting (3) Smartwatch data streaming | (1) Medication reporting (2) Symptoms reporting (3) Smartwatch data streaming (4) Structured motor assessments at home |
Sites | 4 sites in US | 11 sites across US, UK, Austria, Germany |
Devices | Apple Watch, iPhone | Pebble watch, iPhone |
App-based medication reporting | The normal medication regimen of the patient | Pridopidine (interventional investigational drug), twice per day per study protocol: a morning dose between 7:00 and 12:00, and an evening dose 7 to 10 h later |
App-based symptoms reporting | Symptom severity three times per day | Chorea severity during the last five minutes, once per day |
Wearing of smartwatch | A minimum of 12 h per day for 25 days per month | Continuously throughout study duration, preferably between 9:00–21:00 |
Performance of structured motor assessments at home | NA | Every other day, alternating mornings and evenings |